research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
2,000 military advisors from the PRC and the Soviet Union trained the Việt Minh guerrilla force with the aim of turning it into a full-fledged armed force to fight off their French colonial masters and gain national independence. On top of this, the PRC sent two People's Liberation Army (PLA) artillery battalions to fight at the siege of Dien Bien Phu on May 6, 1954, with one battalion operating the Soviet Katyusha multiple-rocket launcher systems (MRLS) against French forces besieged at Dien Bien Phu's valley. From 1950 to 1954 the Chinese government shipped goods, materials, and medicine worth $54 billion (in 2025 dollars) to Vietnam. From 1950 to 1956 the Chinese government shipped 155,000 small arms, 58 million rounds of ammunition, 4,630 artillery pieces, 1,080,000 artillery shells, 840,000 hand grenades, 1,400,000 uniforms, 1,200 vehicles, 14,000 tons of food, and 26,000 tons of fuel to Vietnam. Mao Zedong considered it necessary to buttress the Viet Minh to secure his country's southern flank against potential interference by westerners, while the bulk of the PRC's regular military forces participated in the Korean War from 1950 to 1953. After the end of the Korean War and the resolution of the First Taiwan Strait Crisis, China stepped up involvement in the Indochina Wars, viewing the presence of potentially hostile forces in Indochina as the main threat.
Researchers have hypothesized that the ability of leukocytes to maintain attachment and rolling on the blood vessel wall can be explained by a combination of many factors, including cell flattening to maintain a larger binding surface-area and reduce hydrodynamic drag, as well as tethers holding the rear of the rolling cell to the endothelium breaking and slinging to the front of the rolling cell to reattach to the endothelial wall. These hypotheses work well with Marshall's 2003 findings that selectin bonds go through a catch-slip transition in which initial increases in shear force strengthen the bond, but with enough applied force bond lifetimes begin to decay exponentially. Therefore, the weak binding of a sling at the leading edge of a rolling leukocyte would initially be strengthened as the cell rolls farther and the tension on the bond increases, preventing the cell from dissociating from the endothelial wall and floating freely in the bloodstream despite high shear forces. However, at the trailing edge of the cell, tension becomes high enough to transition the bond from catch to slip, and the bonds tethering the trailing edge eventually break, allowing the cell to roll further instead of remaining stationary.
=== Non-destructive testing === Nuclear magnetic resonance is extremely useful for analyzing samples non-destructively. Radio-frequency magnetic fields easily penetrate many types of matter and anything that is not highly conductive or inherently ferromagnetic. For example, various expensive biological samples, such as nucleic acids, including RNA and DNA, or proteins, can be studied using nuclear magnetic resonance for weeks or months before using destructive biochemical experiments. This also makes nuclear magnetic resonance a good choice for analyzing dangerous samples.
=== Excretion === The elimination of 2,6-DCBQ and its derivatives occurs predominantly through the renal system. Due to its high reactivity, levels of the unchanged parent compound are negligible. Instead, the compound is excreted in the form of water-soluble metabolites, specifically mercapturic acid derivatives. Biliary excretion is a secondary possibility, but urinary elimination remains the dominant pathway for the clearance of 2,6-DCBQ metabolites from the body.
Sources: en.wikipedia.org
=== Breast cancer === Pregnancy has a positive effect on the prognosis of breast cancer according to several studies and it apparently increases the chance of survival after diagnosis of breast cancer. Possible positive effects of pregnancy could be explained by the persistence of fetal cells in the blood and maternal tissues. Fetal cells are probably actively migrating from peripheral blood into the tumor tissue where they are preferentially settled in the tumor stroma and one their concentration decreases as they get closer to the healthy breast tissue. There are two suggested mechanisms by which the fetal cells could have the positive effect on the breast cancer prognosis. The first mechanism suggests that fetal cells only oversee cancer cells and they attract components of the immune system if needed. The second option is that the down-regulation of the immune system induced by the presence of fetal cells could ultimately lead to cancer prevention, because women in whom FMC is present produce lower concentrations of inflammatory mediators, which may lead to the development of neoplastic tissue. The effect also depends on the level of microchimerism: Hyperchimerism (a high rate of microchimerism) and hypochimerism (a low rate of microchimerism) can be related to the negative effect of FMC and thus can promote a worse prognosis of breast cancer. Apparently, women with breast cancer may fail in the process of obtaining and maintaining allogeneic fetal cells.
=== Mbizo Cricket Centre === The largest venture by the Mid West Rhinos is the ongoing Mbizo Cricket centre project. Aimed at developing cricket in the underprivileged high density suburb of Mbizo, the cricket centre was part funded by the Australian Embassy and Indian auto mobile manufacturer Mahindra. The project has been vital in increasing awareness and knowledge of cricket in the area and has resulted in producing a number of decent cricketers. The project stalled in 2014 but in 2015, the Australian Embassy and prominent businessmen John and Charles Gardiner of the Cold Chain Group provided funds to complement the existing facilities with a large pavilion. Still under construction, the pavilion will include changing rooms, kitchen, running water, electricity and meeting areas. Whilst the project was slow to gain ground, the support from the local community was immense. When club cricket was played at the centre it would not be unusual to see 60 players arriving on match day vying for a place on the team. Many of the cricketers who played for Mbizo have gone on to represent other local league teams and some have even appeared for the Rhinos.
The Hispanic population in Belize makes up about half of the population and consists of two main groups, the Yucatec Mestizos, better known as Mestizos, and the Central American immigrants from El Salvador, Guatemala, Honduras and Nicaragua. The Yucatec Mestizos are people of mixed Spanish and Yucatec Maya descent. They were the first to bring Catholicism and the Spanish language to Belize after various failed attempts over the century by Spanish conquistadores. They originally came to Belize in 1847, to escape the Caste War, which occurred when thousands of Mayas rose against the state in Yucatán and over one-third of the population was massacred. The survivors fled across the borders into British territory. The Mestizos are found everywhere in Belize but most make their homes in the northern districts of Corozal and Orange Walk. In the 1980s a wave of Central American migrants from El Salvador, Guatemala, Honduras, and Nicaragua came to settle in Belize. The Government of Belize with the help of the United Nations opened the nation's doors to Central American neighbours fleeing from civil war and persecution. Due to the influences of Belizean Creole and English, many Mestizos speak what is known as "Kitchen Spanish". The mixture of Yucatec Mestizo and Yucatec Maya foods like tamales, escabeche, chirmole, relleno, and empanadas came from their Mexican side and corn tortillas were handed down by their Mayan side. Music comes mainly from the marimba, but they also play and sing with the guitar.
== Pregnancy == About 50% of women experience low back pain during pregnancy. Some studies have suggested that women who have experienced back pain before pregnancy are at a higher risk of experiencing back pain during pregnancy. It may be severe enough to cause significant pain and disability in as many as one third of pregnant women. Back pain typically begins at approximately 18 weeks of gestation and peaks between 24 and 36 weeks. Approximately 16% of women who experience back pain during pregnancy report continued back pain years after pregnancy, indicating that those with significant back pain are at greater risk of back pain following pregnancy. Biomechanical factors of pregnancy shown to be associated with back pain include increased curvature of the lower back, or lumbar lordosis, to support the added weight on the abdomen. Also, the hormone relaxin is released during pregnancy, which softens the structural tissues in the pelvis and lower back to prepare for vaginal delivery. This softening and increased flexibility of the ligaments and joints in the lower back can result in pain. Back pain in pregnancy is often accompanied by radicular symptoms, suggested to be caused by the baby pressing on the sacral plexus and lumbar plexus in the pelvis. Typical factors aggravating the back pain of pregnancy include standing, sitting, forward bending, lifting and walking.
=== Synthesis === The synthesis of tirzepatide was first disclosed in patents filed by Eli Lilly and Company in 2016. This uses standard solid phase peptide synthesis, with an allyloxycarbonyl protecting group on the lysine at position 20 of the linear chain of amino acids, allowing a final set of chemical transformations in which the sidechain amine of that lysine is derivatized with the lipid-containing fragment. Large-scale manufacturing processes have been reported for this compound.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.